Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT: Ivosidenib maintenance after allogeneic stem cell transplantation in IDH1-mutated AML or high-risk MDS
2023-509055-14-00Phase 2Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Technische Universität Dresden. Primary endpoint: Event-free survival rate at 2 years. Planned start Jun 2025; status: authorised.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-509055-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509055-14-00.